Karyopharm (KPTI) Sell-Off Overdone, Leerink Partners Says

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Karyopharm (KPTI) Sell-Off Overdone, Leerink Partners Says

Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress

August 10, 2015 7:30 AM EDT

Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers

Provides Update to Certain Trials based on Expanding Clinical Experience

Conference Call Scheduled for today at 8:30 a.m. ET

NEWTON, Mass., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported financial results for the second quarter 2015 and commented on recent accomplishments and clinical development plans for selinexor, its lead product candidate.

"Important data describing the clinical benefit of selinexor across multiple solid and hematologic malignancies was... More